Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$74.64 USD

74.64
2,735,485

+0.19 (0.26%)

Updated May 16, 2024 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.

CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

by Zacks Equity Research

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

by Zacks Equity Research

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.

QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft first-quarter performance.

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp

by Zacks Equity Research

10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.

Urmimala Biswas headshot

3 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

Here's Why Boston Scientific (BSX) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

AHCO vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 9.80% and 4.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for These 4 Medical Products Stocks in Q1 Earnings?

by Zacks Equity Research

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.

Unveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable

by Zacks Equity Research

Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.

Boston Scientific (BSX) Faces Rising Costs, Competition

by Zacks Equity Research

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

AHCO or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) and Scivita Medical Expand Partnership

by Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.